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Abstract
Background: Melanoma incidence is on the rise and advanced melanoma carries an extremely poor prognosis.
Treatment options, including chemotherapy and immunotherapy, are limited and offer low response rates and
transient efficacy. Thus, identification of new melanocyte/melanoma antigens that serve as potential novel
candidate biomarkers in melanoma is an important area for investigation.
Methods: Full length MITF-M and its splice variant cDNA were cloned from human melanoma cell line 624 mel by
reverse transcription polymerase chain reaction (RT-PCR). Expression was investigated using regular and quantitative
RT-PCR in three normal melanocytes (NHEM), 31 melanoma cell lines, 21 frozen melanoma tissue samples, 18
blood samples (pheripheral blood mononuclear cell; PBMC) from healthy donors and 12 non-melanoma cancer cell
lines, including three breast, five glioma, one sarcoma, two kidney and one ovarian cancer cell lines.
Results: A novel splice variant of MITF-M, which we named MITF-Mdel, was identified. The predicted MITF-Mdel protein
contains two in frame deletions, 56- and 6- amino acid deletions in exon 2 (from V32 to E87) and exon 6 (from A187 to
T192), respectively. MITF-Mdel was widely expressed in melanocytes, melanoma cell lines and tissues, but almost
undetectable in non-melanoma cell lines or PBMC from healthy donors. Both isoforms were expressed significantly
higher in melanoma tissues than in cell lines. Two of 31 melanoma cell lines expressed only one isoform or the other.
Conclusion: MITF-Mdel, a novel melanocyte/melanoma-specific isoform of MITF-M, may serve as a potential
candidate biomarker for diagnostic and follow-up purposes in melanoma.
Background
The microphthalmia-associated transcription factor
(MITF) is a member of the basic helix-loop-helix leucine
zipper transcription factor family, which plays a central
role in the differentiation of neural crest-derived mela-
nocytes, optic cup-derived retinal pigment epithelial
cells, bone marrow-derived mast cells and osteoclasts
and natural killer cells [1-5]. Mutations in MITF are
associated with auditory-pigmentary syndromes such as
Waardenburg syndrome [6] and Tietz syndrome [7,8]
and result in hearing loss and depigmentation of the
hair and skin.
The MITF gene is expressed in different isoforms that
are under the control of distinct promoters. At least
eight isoforms of human MITF with different N-termini
a r ek n o w n ,M I T F - A [ 9 ] ,M I T F - B [ 1 0 ] ,M I T F - C [ 1 1 ] ,
MITF-D[12], MITF-E[13], MITF-H[14], MITF-J [15]
and MITF-M[16], and are derived from alternative
s p l i c i n go fau n i q u ef i r s te x o n .T h e ya l ls h a r et h e
common downstream exons from 2 to 9. All isoforms
share important functional domains including the trans-
activation domain, basic domain, and helix-loop-helix
and leucine-zipper domain (b-HLH-LZ). Distinct iso-
forms may possess cell-specific functions. For example,
MITF-M is exclusively expressed in melanocyte/
melanoma cells and serves as the master gene for mela-
nocyte development, survival and differentiation.
Several studies provide evidence that MITF serves as an
oncogene in human melanoma. MITF amplification was
found in 15-20% of metastatic melanoma, and is asso-
ciated with decreased 5-year survival [17]. In addition,
transformation of immortalized human melanocytes
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BRAF (V600E) [17].
The diagnosis of metastatic melanoma most often
relies on S100 and HMB-45 melanoma biomarkers [18].
However, S100 is highly sensitive but not very specific
as it also stains other nonmelanoma cancers. In contrast,
HMB-45 is highly specific for melanoma but not very
sensitive as it may miss a significant of melanoma cases.
Therefore, the combination of both S100 and HMB-45
is often used to improve their diagnostic utility [18].
MITF has been shown to be superior to the S100 and
HMB-45 combination in both sensitivity and specificity
in the diagnosis of melanoma [18].
One of the most difficult decisions in the treatment
of melanoma is whether a particular patient needs
adjuvant therapy. Current approaches to adjuvant ther-
apy in melanoma, including the use of high dose inter-
feron-a, are associated with significant toxicity but with
modest benefits. Therefore, it is important to have ways
of identifying which patients are at higher risk of
relapse and, therefore, may benefit from adjuvant ther-
apy. One of the strategies that have been widely studied
is the detection of circulating tumour cells, using a
variety of molecular biomarkers. The most commonly
used markers are the melanoma/melanocyte tissue-
differentiation antigens, including tyrosinase and mela-
noma-associated antigen recognized by T cells
(MART-1). However, the lower than expected frequency
of detection of circulating tumor cells using these
assays may limit their clinical utility [19]. Unlike other
biomarkers in melanoma, MITF is expressed at various
levels in almost all melanoma specimens [18,20]. This is
most probably due to its essential function in the survi-
val of the melanocyte linage [18,20]. In addition, MITF
detection after treatment was a significant independent
prognostic factor for relapse-free and overall survival
[21]. Therefore, MITF or MITF isoforms have the
potential of being an important biomarker for
melanoma.
Here we report a novel splicing variant of MITF-M,
which we named MITF-Mdel. This variant was cloned
from the human melanoma cell line 624 mel. Compared
with wild-type MITF-M, MITF-Mdel has two in-frame
deletions. The 56-amino acid deletion from V32 to E87
in exon 2 has not been previously reported in human.
The 6-amino acid deletion, ACIFPT, from A187 to T192
of MITF-M in exon 6 has been previously reported in
MITF-A, -D and -H isoforms [1,4,5]. We found that
MITF-Mdel was widely expressed in normal human mel-
anocytes and melanoma cell lines as well as primary
melanoma tissues, but was almost undetectable in non-
melanoma cancer cell lines and pheriperal blood mono-
nuclear cell (PBMC) from healthy donors. Our finding
showed that MITF-Mdel expression is melanocyte/
melanoma specific and thus potentially a valuable candi-
date biomarker for melanoma.
Methods
Cancer cell lines
All cell lines, including 31 melanoma, five glioma, four
breast, two colon, one ovarian, one sarcoma, and one
kidney cancer cell lines, in this study were grown in
RPMI 1640 medium containing 10% heat-inactivated
fetal calf serum and 100 units/ml penicillin-streptomycin
Sigma-Aldrich (MO, USA). Normal human melanocytes
(NHEM) were grown in Melanocyte Cell Basal Medium-
4 with growth supplements (Clonetics MGM-4™ Bullet-
Kit (CC-3249), Cambrex, NJ, USA). The cells were har-
vested for RNA isolation when they were approximately
70-80% confluent and in healthy condition.
Blood and frozen melanoma tissue samples
PBMC from 20 healthy donors and frozen primary mel-
anoma tissue samples were used in this study. PBMC
was isolated from normal donors’ buffy coats using a
standard density gradient centrifugation method (Ficoll,
Invitrogen, CA, USA). Blood samples and 21 frozen
melanoma tissue samples were used for RNA isolation
using an RNA extraction kit (RNeasy Total RNA, Qia-
gen, CA, USA), following the manufacture’s instructions.
Buffy coats from anonymous health donors were
obtained from the regional American Red Cross blood
bank. All melanoma tissue samples were cryopreserved
within 10 min of surgical excision in liquid nitrogen and
stored within the Tissue Procurement Laboratory of the
Moffitt Cancer Center as described previously [22].
Cloning of Mitf-M isoforms
Total RNA was isolated from human melanoma cell line
624 mel and treated with RNase-free DNase I for 30
min. RT was performed simultaneously with oligo (dT)
with first strand cDNA synthesis kit (Amersham Bios-
ciences, NJ, USA). MITF-M primer design was based on
published sequence of human MITF mRNA [17]. The
full-length human MITF-M cDNA, which was isolated
using the forward primer 5’-gcagatctatgctggaaatgctagaa-
tataat-3’ and reverse primer 5’-gaattcacaagtgtgctccg-3’,
was cloned into pCDNA3.1/V5-his topo vector (Invitro-
gen, CA, USA). After restriction enzyme digestion
screening, two types of human MITF-M constructs were
identified based on agarose gel analysis.
DNA sequencing
Sequencing of the isolated human MITF-M clones was
performed by the Biotechnological Laboratory Core
Facility at Northwestern University. Searches for
sequence homology were performed with the GeneBank
database using the BLAST algorithm.
Wang et al. BMC Medicine 2010, 8:14
http://www.biomedcentral.com/1741-7015/8/14
Page 2 of 9Expression analysis by RT-PCR and quantitative
PCR (qPCR)
Total RNA was extracted from the three NHEMs, 31
melanoma cell lines, 21 frozen melanoma tissue samples
(Frtu), 18 blood samples (PBMC) from healthy donors,
and 12 non-melanoma cancer cell lines, including three
breast, five glioma, one sarcoma, two kidney and one
ovarian cancer cell lines using an RNA extraction kit
(RNeasy Total RNA, Qiagen, CA, USA) according to the
instructions. Total RNA was treated with DNase I (Pro-
mega, WI, USA) to avoid residual genomic DNA con-
tamination. First-strand cDNA was synthesized using a
First-Strand Synthesis system (ABgene, Epsom, UK) for
regular RT-PCR reaction. Wild type MITF-M was ampli-
fied using primer pairs 5’-ttatagtaccttctctttgccagtcc-3’
(human MITF-M specific forward primer) and 5’-ctta-
taaaatccctctttttcacagttgga-3’ (reverse). Deletion isoform,
MITF-Mdel, was amplified using the same MITF-M spe-
cific forward primer and the MITF-Mdel specific reverse
primer 5’-cttataaaatccctgccgttgg-3’. The cDNA for qPCR
was obtained using high capacity cDNA archive kit
(Applied Biosystems, CA, USA) according to the instruc-
tions. qRT-PCR was performed using the Bio-Rad iQ5
real time PCR machine coupled with SYBR Green chem-
istry (Applied Biosystems, CA, USA). The primers are
listed in Table 1. All PCR reactions were in 25 μL of total
volume containing 12.5 μLo fS Y B Rg r e e nP C Rm a s t e r
mix, 40 ng cDNA, 300 nM of each primer. All amplifica-
tions were done in triplicate for each sample and
repeated once. The thermal cycling was 10 min at 95°C,
followed by 40 cycles at 95°C for 15 s, at indicated
annealing temperature for each gene in Table 1 for 20 s,
and at 72°C for 30 s. The specificity of amplification was
monitored using the dissociation curve of the amplified
product. Relative expression of the target genes was cal-
culated using delta Ct method, and 624 mel was used as
a normalization control.
Statistical analysis
Quantitative PCR data were expressed as median. The
Student t-test was used in the analysis. Frequency rate
was analysed by chi square test. P < 0.05 was considered
statistically significant.
Results
Identification of a novel isoform of MITF-M, MITF-Mdel
The MITF-M cDNA fragment was obtained by RT-PCR
of the mRNA from human melanoma cell line 624 mel
and cloned into the pCDNA3.1/V5-his topo vector.
After digestion by EcoRI and BglII, two distinctly differ-
ent patterns were identified on agarose gel. DNA
sequencing revealed that one was wild type MITF-M,
and the other was a novel isoform of MITF-M, which
w en a m e dM I T F - M d e l .C o m p a r e dw i t hw i l dt y p e
MITF-M, MITF-Mdel contained two in-frame deletions
(Figure 1). One deletion was in exon 2, with 168 bp
(from 94G to 261G in the coding region of MITF-M) at
mRNA level or 56- amino acid (from V32 to E87) at
protein level, which had not been previously reported in
human. The other deletion, with 18 bp (from 560C to
577G in the coding region of MITF-M) at mRNA level
or 6-amino acid (from A187 to T192) at protein level,
was located in exon 6, upstream from the basic region,
and had previously been described [1,4,5]. However, the
MITF-Mdel isoform still contained an entire basic helix-
loop-helix leucine zipper domain, an important func-
tional domain in MITF proteins (Figure 2a and 2b).
MITF-Mdel sequence was deposited in GenBank
(Accession No. GU355676).
Expression profiles of MITF-M and MITF-Mdel
The expression profiles of the two MITF-M isoforms in
various tumor cell lines, normal human melanocytes, fro-
zen fresh melanoma tissue samples and normal PBMC
samples were analysed by RT-PCR and quantitative RT-
PCR. As seen in Table 2, three of four melanocyte sam-
ples (75%), 29 of 31 melanoma cell lines (93.5%) and 21
of 21 frozen fresh melanoma tissue samples (100%) were
positive for MITF-Mdel. Similar results were also
obtained for wild type MITF-M. In addition, 30 of 31
melanoma cell lines (96.8%) were positive for either iso-
form. MITF-M and MITF-Mdel had similar patterns of
expression. In this RT-PCR assay, they were found to be
expressed only in normal human melanocytes, melanoma
cell lines, and fresh melanoma tissues. Most expressed
both MITF-M isoforms, while 2 of 31 melanoma cell
lines expressed one or the other. Neither normal PBMC
samples nor non-melanoma cancer cell lines analysed,
including five glioma (LN229, A172, U138, U87 and
U373), three breast (MDA-MB-231, SKBR3 and MCF-7),
one ovarian (ES2), one sarcoma (6647), one kidney and
two colon (Colo320 and T84) cancer cell lines were
found to express either isoform of MITF-M (Figure 3).
RT-qPCR showed similar results as regular RT-PCR
(Figure 4a and 4b). 624 mel cell line was used as a refer-
ence to normalize measurements from real-time PCR.
The mRNA expression level of MITF-M and MITF-Mdel
Table 1 Primer sequences for mRNA analysis by real-time
polymerase chain reaction.
Gene Primers (human) Amplicon Tm
GADPH F: 5’-cgagatccctccaaaatcaa-3’; 170 60
R: 5’-ttcacacccatgacgaacat-3’
MITF-M F: 5’-ttatagtaccttctctttgccagtcc-3’ 146 52
R: 5’-gtttatttgctaaagtggtagaaaggtact-3’
MITF-Mdel F: 5’-ttatagtaccttctctttgccagtcc-3’; 120 52
R: 5’-cttataaaatccctgccgttgg-3’
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tion of mRNA status among samples, relative mRNA
expression level of MITF-M and MITF-Mdel were used
to assess the cutoff point. The cutoff point was above the
mean relative MITF-M or MITF-Mdel plus 5 × SD of
normal PBMCs. We set the cutoff for MITF-M and
MITF-Mdel positivity at 10% of the mRNA expression
level of those in 624 mel cell line.
The cutoff line for MITF-M was above the MITF-M
levels of all normal PBMCs and all but one of the non-
melanoma cell lines, but above the MITF-M levels of 25
of 30 (83.3%) melanoma cell lines, and 19 of 21 (90.5%)
frozen melanoma tissue samples. While the cutoff line
for MITF-Mdel was above MITF-Mdel levels of all nor-
mal PBMCs and all of the non-melanoma cell lines, but
above the MITF-Mdel levels of 22 of 30 (73.3%) mela-
noma cell lines, and 18 of 21 (85.7%) frozen melanoma
tissue samples. Specimens with higher relative MITF-M
or MITF-Mdel expression level than the cutoff point
were considered as positive for MITF-M or MITF-Mdel.
Both MITF-Mdel and MITF-M levels of expression in
frozen melanoma tissue samples were significantly
higher than those in melanoma cell lines (P = 0.0001),
PBMCs from normal donors (P < 0.0001) and all of the
non-melanoma cell lines (P < 0.0001).
Discussion
In this report, MITF-Mdel, a novel melanocyte/mela-
noma-specific isoform of MITF-M, was cloned from the
human melanoma cell line 624 mel. The predicted
MITF-Mdel protein contains two in frame deletions, 56-
and 6- amino acid deletions in exon 2 (from V32 to
E87) and exon 6 (from A187 to T192), respectively. The
former deletion had not been previously reported.
MITF-Mdel was widely expressed in melanocytes, mela-
noma cell lines and tissues, but almost undetectable in
non-melanoma cell lines or PBMC from healthy donors.
Both isoforms were expressed significantly higher in
Figure 1 Mutation analysis. (A-E) Sequence traces showing the splicing site mutation of human microphthalmia-associated transcription factor
(MITF)-M. (A&B) Sequence of exon 2 of wild-type MITF-M using the forward primer. (C) Sequence of exon 6 of wild-type MITF-M using the
reverse primer. (D) Sequence of exon 2 of the MITF-Mdel using the forward primer. (E) Sequence of exon 6 of the MITF-Mdel using the reverse
primer. The nucleotides between the underlined nucleotides indicate the deletion regions. (F) Schematic representation of the structures of
MITF-M and MITF-Mdel. The MITF-Mdel isoform has a 168-bp in-frame deletion in exon 2 and an 18-bp in-frame deletion in exon 6, but still has
the transcriptional activation domain, the b-HLH-LZ domain and the serine-rich region (S).
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noma cell lines expressed only one isoform or the other.
As seen in Figure 4, the medians of relative expression
of MITF-M and MITF-Mdel by qRT-PCR are compar-
able. Therefore, MITF-Mdel seems to be a common iso-
form in melanoma. At this time, we do not know if
there are differences in the relative amounts of each iso-
form in melanocytes versus primary melanoma versus
metastatic melanoma. By correlating the differential
expression of these MITF-M isoforms in primary and
metastatic melanoma tissues with progression free survi-
val and overall survival in future studies, we may be able
to validate the utility of MITF-Mdel as a biomarker.
We analyzed the sequence of MITF-Mdel and the
168-bp deletion in exon 2 and found a cryptic splice
donor site ‘GTAAA’ [23] at the beginning of the 168-bp
deletion. The last nucleotide of the 168-bp deletion is at
the exon-intron boundary and can be considered as the
Figure 2 cDNA and amino-acid sequences of human microphthalmia-associated transcription factor (MITF)-M and MITF-Mdel.( A )
Alignment of mRNA sequences of MITF-M and MITF-Mdel. MITF-Mdel contains 168-bp and 18-bp in-frame deletions at mRNA level. (B)
Alignment of predicted protein sequences of MITF-M and MITF-Mdel. MITF-Mdel is predicted to encompass 357 amino acids. The underlined
portion marks the basic-helix-loop-helix domain. Compared with MITF-M, MITF-Mdel has deletions of 56-amino acid (from V32 to E87) in exon 2
and 6-amino acid (from A187 to T192) in exon 6. Dash lines represent deletions. Red highlighting indicates alternate exons. Green highlighting
indicates amino acids encoded across a splice junction.
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tion for the generation of MITF-Mdel splice variant.
In addition, human MITF-M mRNA with an 18-bp
deletion has been shown to result from alternative spli-
cing using two acceptor sites located at the 5’end of
exon 6 [24].
Similar to MITF-M, MITF-Mdel is driven by the M
promoter and contains the transcriptional activation
domain, the b-HLH-LZ domain and the serine-rich
region. Whether the 168-bp deletion in exon 2 of
MITF-Mdel has any phenotypic or functional conse-
quence is not known at this time. Since serine 73
(Ser73), which is phosphorylated by mitogen activated
protein kinase cascade, is located in exon 2B of the
MITF gene, the newly discovered deletion from V32 to
E87 effectively removes this phosphorylation site in
MITF. Phosphorylation does not seem to affect accumu-
lation of MITF in the nucleus [25]. However, mutation
at Ser73 has been shown to reduce MITF’st r a n s c r i p -
tional activity on the tyrosinase promoter [25,26]. Other
recent studies did not support the essential role of
Ser73 or of exon 2 in the function of MITF. The serine
to alanine mutation (Ser73Ala) did not alter the pheno-
type of the mutant mice [27]. In addition, deletion of
exon 2 did not affect the function of MITF [28].
Melanoma cell line 1973 carries only the MITF-Mdel
isoform and not the wild-type MITF; whereas melanoma
cell line 624 carries both isoforms (Figure 3). From our
previous study, it seems that MITF is still functional in
1973 mel. Downstream target genes for MITF, including
Table 2 Detection of microphthalmia-associated transcription factor (MITF)-M and MITF-Mdel mRNA expression in
normal human melanocytes (NHEM) and melanoma by reverse transcriptase polymerase chain reaction.
MITF-M (+) MITF-Mdel (+) MITF-M or MITF-Mdel (+)
No. % No. % No. %
NHEM 3/4 75% 3/4 75% 3/4 75%
Melanoma cell lines 29/31 93.5% 29/31 93.5% 30/31 96.8%
Melanoma tissue samples 21/21 100% 21/21 100% 21/21 100%
Figure 3 Detection of microphthalmia-associated transcription factor (MITF)-Mdel and MITF-M in melanoma cell lines and other
carcinoma cell lines by reverse transcriptase polymerase chain reaction (representative results). MITF-M and MITF-Mdel have similar
expression profiles. Similar to MITF-M, MITF-Mdel was found to be expressed only in normal human melanocytes, melanoma cell lines, and fresh
melanoma tissues. Both isoforms were also expressed in MDA-MB-435, a cell line originally thought to be a breast cancer cell line, but has been
identified as a melanoma cell line. Most melanoma expressed both MITF-M isoforms while two melanoma cell lines expressed only one or the
other. Melanoma cell lines (n = 31; only 16 shown): from 501 to 2351, and MDA-MB-435. Breast carcinoma cell lines (n = 3; only two shown):
MDA-MB-231 and SKBR3. Colon cancer cell lines (n = 2): T84 and Colo320. Ovarian cancer cell line (n = 1): ES2. Glioma cell lines (n = 5; only two
shown): U138 and U87. PBMC No.7 and No.8 from healthy donors. Normal human melanocytes (NHEM) 7251 and NHEM2486: normal human
melanocytes.
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and MART-1, were expressed at comparable levels as
those expressed in 624 mel [29].
Since adjuvant treatments for melanoma may have
limited benefits but much potential toxicity, the ability
to identify patients at high risk for recurrence is essen-
tial in the development of an effective adjuvant therapy.
A highly sensitive RT-PCR and real-time quantitative
RT-PCR offer a platform for monitoring circulating mel-
anoma cells to potentially predict melanoma prognosis
and identify high-risk patients for further treatment.
Tyrosinase, MART-1, and gp100 are melanocyte/mela-
noma-differentiation antigens that are frequently
expressed in melanoma cells and not in non-melanoma
tumours. In one study, circulating tyrosinase and
MART-1 mRNA was detected in only 77% and 54%,
Figure 4 Relative expression of microphthalmia-associated transcription factor (MITF)-M (A) and MITF-Mdel (B) in 31 melanoma cell
lines, 21 frozen melanoma tissue samples, 18 PBMCs from healthy donors, and 12 non-melanoma cell lines, including three breast,
five glioma, one sarcoma, two kidney and one ovarian cancer cell lines. Data was calculated using ΔΔCt method. Melanoma cell line 624
mel was used as normalization control and its MITF-M and MITF-Mdel relative expression levels were set as 100%. Bars indicated median of
expression levels of MITF-M or MITF-Mdel mRNA in each group.
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melanocyte/melanoma-specific marker that has been
used to detect circulating tumour cells. In a recent
study, MITF expression by quantitative RT-PCR was
almost undetectable in PBMC of healthy blood donors,
as in our study. However, it was detected in 86% of mel-
anoma tissue samples. The rate of circulating MITF
detection was higher with increasing melanoma stages.
MITF detection after treatment was a significant inde-
pendent prognostic factor for relapse-free and overall
survival [21].
Conclusions
The novel isoform MITF-MDel was widely expressed in
melanocytes, melanoma cell lines and tissues, but almost
undetectable in non-melanoma cell lines or PBMC from
healthy donors, and may serve as a potential candidate
biomarker for diagnostic and follow-up purposes in
melanoma.
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